Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06634459 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment

Study acronym: POMEGRANATE
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Apr 2026 → Jan 2027
See other at-risk trials from Medstar Health Research Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Apr 2026 to Jan 2027
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study completion pushed from Oct 30, 2026 to Jan 2027
    • Site details revised at 9 of 9 sites
    v12
  2. Minor Enrollment target: 200 to 218
    • Site contacts updated at 1 of 9 sites
    v11
  3. Minor Enrollment target: 182 to 200
    • Primary completion date: Oct 2025 to Apr 2026
    • Site contacts updated at 1 of 9 sites
    v10
  4. Minor Re-verified, no change to tracked fieldsv9
  5. Notable Primary endpoint revised
    • Site contacts updated at 1 of 9 sites
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 8 to 9
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: 8 to 10
    v7
  2. Minor Study sites: 7 to 8v6
  3. Minor Study sites: 4 to 7v5
  4. Minor Study sites: 1 to 4v4
  5. Minor Study completion date: Oct 2026 to Oct 30, 2026
    • Start date changed from estimate of Oct 2024 to Nov 1, 2024
    • Site contact updated
    v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study site revised
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multi-centered, randomized controlled trial will evaluate the safety and efficacy of home use of the novel Reia System (RS), which includes the Reia pessary and applicator, compared to standard pessary care (Gellhorn or ring with/without support without knob) among women with stage II-IV pelvic organ prolapse (POP). A total of 200 participants will be recruited among pessary naïve patients who are symptomatic and choose a vaginal pessary for management of their POP from study sites specializing in Urogynecology and Reconstructive Pelvic Surgery (URPS). Participants will be assigned via 1:1 randomization using computer generated numbers in permutated groups of variable block sizes to either the intervention (the Reia System, RS) or standard pessary care (SPC) stratified by site. Participation in this trial will involve a total of four visits over six months. The primary outcome measure will be satisfaction measured at the six-month time point. Secondary outcomes will include validated surveys to assess quality of life, number of self-management events, ease/difficulty of pessary insertion/removal, importance of ability to self-manage pessary, and adverse events. Specific Aims Aim 1: To compare satisfaction with pessary use and management between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 2: To assess successful fitting, number of refitting visits, number of self-management events and continued pessary use over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 3: To compare ease/difficulty of pessary use and importance of ability to self-manage, as well as quality of life over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 4: To measure rates of adverse events and risk factors for adverse events over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary.
Trial Details
NCT Number NCT06634459
Lead Sponsor Medstar Health Research Institute
Conditions
(from sponsor)
Pelvic Organ Prolapse, Prolapse
Related terms Pelvic Organ Prolapse, Prolapse
Enrollment 218 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov